Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen

Journal of Bone and Mineral Research

Volumn 18, Issue 2, 2003, Pages 237-243

  Marini, Joan C ^a   Hopkins, Elizabeth ^a   Glorieux, Francis H ^b   Chrousos, George P ^a   Reynolds, James C ^c   Gundberg, Caren M ^d   Reing, C Michael ^e  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d YALE UNIVERSITY   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Carboxyterminal propeptide; DXA; Growth hormone; Histomorphometry; Osteogenesis imperfecta

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; OSTEOCALCIN; PROCOLLAGEN C PROTEINASE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATROPIN NUTROPIN;

ARTICLE; BODY HEIGHT; BONE DENSITY; BONE MARROW BIOPSY; BONE MATRIX; BONE METABOLISM; CANCELLOUS BONE; CHILD; CLINICAL ARTICLE; FEMALE; FRACTURE; GROWTH RATE; HUMAN; LONG BONE; MALE; MORPHOMETRICS; OSSIFICATION; OSTEOGENESIS IMPERFECTA; SHORT STATURE; TRABECULAR BONE; TREATMENT OUTCOME; VERTEBRA;

ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY; CELL DIVISION; CHILD; CHILD, PRESCHOOL; COLLAGEN; COLLAGEN TYPE I; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; OSTEOCALCIN; OSTEOGENESIS IMPERFECTA; PEPTIDES; PROCOLLAGEN; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS;

EID: 0037304052     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2003.18.2.237     Document Type: Article

References (31)

1. Byers PH 1993 Osteogenesis imperfecta. In: Royce PM, Steinmann B (eds.) Connective Tissue and Its Heritable Disorders. Wiley-Liss, New York, NY, USA, pp. 317-50.
2. Sillence DO, Senn A, Danks DM 1979 Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101-116.
3. Marini JC, Bordenick S, Heavner G, Rose S, Chrousos GP 1993 Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta. Am J Med Genet 45:261-264.
4. Antoniazzi F, Bertoldo, F, Mottes, M, Valli M, Sirpresi S, Zamboni G, Valentini R, Tato L 1996 Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr 129:432-439.
5. Marini JC, Bordenick S, Heavner G, Rose S, Hintz R, Rosenfeld R, Chrousos GP 1993 The growth hormone and somatomedin axis in short children with osteogenesis imperfecta. J Clin Endocrinol Metab 76:251-256.
6. Marini JC, Bordenick S, Chrousos G 1995 Endocrine aspects of growth deficiency in OI. Connect Tissue Res 31:S55-S57.
7. Smith WL, Nam TJ, Underwood LE, Busby WH, Celnicker A, Clemmons DR 1993 Use of insulin-like growth factor-binding protein-2 (IGFBP-2). IGFBP-3, and IGF-I for assessing growth hormone status in short children. J Clin Endocrinol Metab 77:1294-1299.
8. Melkko J, Niemi S, Ristelli L, Risteli J 1990 Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36/7:1328-1332.
9. Andrade OMA, Garcia-Mayor RV, Gonzales LD, Rodriguez ST, Segura DA, Alvarez-Novoa R, Antelo CJ 1995 Serum insulin-like growth factor (IGF) binding protein-3 and IGF-I levels during childhood and adolescence. Pediatr Res 38:149-155.
10. Crofton PM, Stirling HF, Schonau E, Kelnar CJH 1995 Bone alkaline phosphatase and collagen markers as early predictors of height velocity response to growth-promoting treatments in short normal children. Clin Endocrinol (Oxf) 44:385-394.
11. Cole DEC, Carpenter TO, Gundberg CM 1985 Serum osteocalcin concentrations in children with metabolic bone disease. J Pediatr 106:770-776.
12. Parfitt AM, Drener MK, Glorieux FH, Kanis JA, Malluche H, Meunier PF, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
13. Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM 2000 Normative data for iliac bone histomorphometry in growing children. Bone 26:103-109.
14. Saggese G, Baroncelli GI, Bertellone S, Cinquanta L, Di Nero G 1993 Effects of long-term treatment with growth hormone on bone and mineral metabolism in children with growth hormone deficiency. J Pediatr 122:37-45.
15. Rauch F, Travers R, Parfitt AM, Glorieux FH 2000 Static and dynamic histomorphometry in children with osteogenesis imperfecta. Bone 26:581-589.
16. Parfitt AM, Travers R, Rauch F, Glorieux FH 2000 Structural and cellular changes during bone growth in healthy children. Bone 27:487-494.
17. Spiliotis BE, August GP, Hung W 1984 Growth hormone neurosecretory dysfunction. JAMA 251:2223-2230.
18. Saggese G, Bertelloni S, Baroncelli GI, Di Nero G 1992 Serum levels of carboxyterminal propeptide of type I procollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur J Pediatr 151:764-768.
19. Saggese G, Baroncelli GI, Bertelloni L, Cinquanta L, Di Nero G 1994 Twenty-four hour osteocalcin, carboxyterminal propeptide of type I procollagen, and amino terminal propeptide of type III procollagen rhythms in normal and growth-retarded children. Pediatr Res 35:409-415.
20. Trivedi P, Risteli L, Risteli L, Hindmash PC, Brook CG, Mowat AP 1991 Serum concentrations of type I and III procollagen propeptides as biochemical markers of growth velocity in healthy infants and children and in children with growth disorders. Pediatr Res 30:276-280.
21. Tapanainen P, Knip M, Risteli L, Kemppainen L, Kaar M-L, Risteli J 1997 Collagen metabolites in the prediction of response to GH therapy in short children. Eur J Endocrinol 37:621-625.
22. Tanaka H, Kubo T, Yamate T, Ono T, Kanzaki S, Seino Y 1998 Effect of growth hormone therapy in children with achondroplasia: Growth pattern, hypothalamic-pituitary function, and genotype. Eur J Endocrinol 138:275-280.
23. Seino Y, Moriwaki T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H 1999 Molecular defects in achondroplasia and the effects of growth hormone treatment. Acta Paediatr Suppl 428:118-120.
24. Petryk A, Richton S, Sly JP, Blethen SL 1999 The effect of growth hormone treatment on stature in Aarskog syndrome. J Pediatr Endocrinol Metab 12:161-165.
25. Sas TCJ, Keizer-Schrama SM, Stijnen T, Jansen M, Otten Bj, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Sosen JJ, Rongen-Westerlaken C, Drop SL 1999 Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: Results of a randomized dose-response trial. J Clin Endocrinol Metab 84:4607-4612.
26. Hochberg Z, Zadik Z 1999 Final height in young women with Turner syndrome after GH therapy: An open controlled study. Eur J Endocrinol 141:218-224.
27. Van den Broeck J, Van Teunenbroek A, Hokken-Koelaga A, Wit J-M and the European Study Group 1999 Efficacy of long-term growth hormone treatment in Turner's Syndrome. J Pediatr Endocrinol Metab 12:673-676.
28. Vetter U, Fisher LW, Mintz KP, Koop JB, Tuross N, Termine JD, Robey PG 1991 Osteogenesis imperfecta: Changes in noncollagenous proteins in bone. J Bone Miner Res 6:501-505.
29. Fedarko NS, Robey PG, Vetter U 1995 Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J Bone Miner Res 10:1122-1129.
30. Robey PG, Termine JD 1985 Human bone cells in vitro. Calcif Tissue Int 37:453-460.
31. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952.